Patents by Inventor Gene Kurosawa
Gene Kurosawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10030071Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.Type: GrantFiled: September 5, 2014Date of Patent: July 24, 2018Assignees: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Kazuhiro Morishita, Kazuko Kaneda, Yoshikazu Kurosawa, Gene Kurosawa, Katsuyuki Mitomo, Katsushi Kouda, Yoshinori Ukai
-
Patent number: 9598496Abstract: An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).Type: GrantFiled: May 7, 2012Date of Patent: March 21, 2017Assignees: PERSEUS PROTEOMICS INC., UNIVERSITY OF MIYAZAKIInventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Patent number: 9593165Abstract: The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.Type: GrantFiled: November 8, 2013Date of Patent: March 14, 2017Assignees: UNIVERSITY OF MIYAZAKI, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Patent number: 9388249Abstract: The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.Type: GrantFiled: April 30, 2014Date of Patent: July 12, 2016Assignee: AMANO ENZYME INC.Inventors: Atsushi Sugioka, Gene Kurosawa, Mariko Sumitomo, Yoshikazu Kurosawa
-
Publication number: 20160194400Abstract: It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.Type: ApplicationFiled: September 5, 2014Publication date: July 7, 2016Applicants: UNIVERSITY OF MIYAZAKI, FUJITA HEALTH UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Kazuhiro MORISHITA, Kazuko KANEDA, Yoshikazu KUROSAWA, Gene KUROSAWA, Katsuyuki MITOMO, Katsushi KOUDA, Yoshinori UKAI
-
Patent number: 9273140Abstract: To provide a method for detecting cellular DNA damage by specifically recognizing molecules responsive to DNA strand breaks. A method for detecting DNA damage in cells, which comprises administering in vivo, to cells, an antibody against a cell membrane surface antigen that is expressed in cells undergoing DNA strand breaks to a greater extent than in cells not undergoing DNA strand breaks in an environment that causes DNA damage, and analyzing the expression status of the cell membrane surface antigen.Type: GrantFiled: May 10, 2013Date of Patent: March 1, 2016Assignees: FUJITA HEALTH UNIVERSITY, Perseus Proteomics Inc.Inventors: Yoshikazu Kurosawa, Maiko Kurosawa, Gene Kurosawa
-
Publication number: 20150291697Abstract: The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.Type: ApplicationFiled: November 8, 2013Publication date: October 15, 2015Applicants: PERSEUS PROTEOMICS INC., UNIVERSITY OF MIYAZAKIInventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20140235833Abstract: The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.Type: ApplicationFiled: April 30, 2014Publication date: August 21, 2014Applicant: FUJITA HEALTH UNIVERSITYInventors: Atsushi SUGIOKA, Gene KUROSAWA, Mariko SUMITOMO, Yoshikazu KUROSAWA
-
Publication number: 20140114054Abstract: An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).Type: ApplicationFiled: May 7, 2012Publication date: April 24, 2014Applicants: UNIVERSITY OF MIYAZAKI, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu Kurosawa, Kazuhiro Morishita, Lilin Zhang, Gene Kurosawa, Katsuyuki Mitomo, Yukio Sudo, Fumiko Nomura, Yoshinori Ukai
-
Publication number: 20140004536Abstract: To provide a method for detecting cellular DNA damage by specifically recognizing molecules responsive to DNA strand breaks. A method for detecting DNA damage in cells, which comprises administering in vivo, to cells, an antibody against a cell membrane surface antigen that is expressed in cells undergoing DNA strand breaks to a greater extent than in cells not undergoing DNA strand breaks in an environment that causes DNA damage, and analyzing the expression status of the cell membrane surface antigen.Type: ApplicationFiled: May 10, 2013Publication date: January 2, 2014Applicants: PERSEUS PROTEOMICS INC., FUJITA HEALTH UNIVERSITYInventors: Yoshikazu KUROSAWA, Maiko KUROSAWA, Gene KUROSAWA
-
Patent number: 8540987Abstract: Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.Type: GrantFiled: January 23, 2009Date of Patent: September 24, 2013Assignees: Institute for Antibodies Co., Ltd., Japan as Represented by Director-General of National Institute of Infectious Diseases, Osaka Prefecture University Public CorporationInventors: Masachika Azuma, Motohide Takahashi, Shunji Kozaki, Masafumi Mukamoto, Tomoko Kohda, Gene Kurosawa, Yoshikazu Kurosawa
-
Publication number: 20120046451Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.Type: ApplicationFiled: September 21, 2011Publication date: February 23, 2012Applicants: Institute for Antibodies Co., Ltd.Inventors: Yoshikazu Kurosawa, Yasushi Akahori, Nobuhiro Takahashi, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Sari Fujiyama, Susumu Tsutsumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Yoshitaka Iba, Mariko Sumitomo, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita
-
Patent number: 8048992Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.Type: GrantFiled: February 22, 2006Date of Patent: November 1, 2011Assignees: Institute for Antibodies Co., Ltd.Inventors: Yoshikazu Kurosawa, Yasushi Akahori, Nobuhiro Takahashi, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Sari Fujiyama, Susumu Tsustumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Yoshitaka Iba, Mariko Sumitomo, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita
-
Publication number: 20110014211Abstract: Provided herein is a means which is effective for botulism diseases and the prevention of the botulism diseases. Specifically provided is a plurality of human anti-botulinum toxin type-A antibodies having different epitopes from one another. Also specifically provided is a composition for neutralizing botulinum toxin type-A, which comprises a combination of two or more of the antibodies and which has a high neutralizing activity.Type: ApplicationFiled: January 23, 2009Publication date: January 20, 2011Applicants: Institute for Antibodies Co., Ltd., Japan as Represented by Director-General of National Institute of Infectious Disesases, Osaka Prefecture University Public CorporationInventors: Masachika Azuma, Motohide Takahashi, Shunji Kozaki, Masafumi Mukamoto, Tomoko Kohda, Gene Kurosawa, Yoshikazu Kurosawa
-
Publication number: 20090203538Abstract: It is intended to provide a method whereby a plural number of antibodies against cell surface antigens are quickly classified and to provide a method whereby antigens of the thus classified antibodies are quickly identified. Further, it is intended to provide a method of promoting the utilization of the useful data obtained by the above methods. Furthermore, it is intended to provide an antibody which is effective in treating or diagnosing cancer.Type: ApplicationFiled: January 9, 2009Publication date: August 13, 2009Applicant: Institute for Antibodies Co., Ltd.Inventors: Atsushi Sugioka, Mototaka Sugiura, Yasushi Akahori, Nobuhiro Hayashi, Akihiko Takasaki, Miwa Morita, Gene Kurosawa, Mariko Sumitomo, Susumu Tsutsumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Noriko Satou, Masachika Azuma, Yoshinori Ukai, Kazuhiro Suzuki, Yoshikazu Kurosawa, Miho Tanaka, Mamoru Shiraishi
-
Publication number: 20090053243Abstract: It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, and ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.Type: ApplicationFiled: February 22, 2006Publication date: February 26, 2009Applicant: Institute for Antibodies Co., LtdInventors: Yoshikazu Kurosawa, Yasushi Akahori, Nobuhiro Takahashi, Atsushi Sugioka, Nobuhiro Hayashi, Akihiko Takasaki, Kazuhiro Suzuki, Miwa Morita, Gene Kurosawa, Sari Fujiyama, Susumu Tsustumi, Keiko Ogawa, Kazuki Matsuda, Chiho Muramatsu, Yoshitaka Iba, Mariko Sumitomo, Masachika Azuma, Yoshinori Ukai, Kazuhiro Morishita